Investors May be Overlooking This Small, Fast-Growing Bay Area Biotech
You've probably heard those advertisements for "the power of protein," referring to the addition of enzymes to detergent. Source: BioSpace
You've probably heard those advertisements for "the power of protein," referring to the addition of enzymes to detergent. Source: BioSpace
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures. Source: BioSpace
Finding a treatment for Sanfilippo Syndrome is a personal matter for the Lysogene team. Source: BioSpace
The former Biogen CEO is making waves at his new venture, Vir Biotechnology. Source: BioSpace
Ablynx announced the price of its U.S. IPO at $17.50. Source: BioSpace
In addition to the layoffs, the company is also looking to divest its Infectious Disease Business. Source: BioSpace
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year. Source: BioSpace
Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum. Source: BioSpace
Vital Laboratories failed to report production deviations, perform proper product reviews or take needed corrective actions at its Gujarat, India, facility, the FDA said in a warning letter. Source: Drug…
Two new FDA draft guidances provide updates for developers on drug-drug interaction. Source: Drug Industry Daily